Week 5

Question 1

List the flow cytometry markers for T-Cells

Answer 1

CD 2, 3, 4, 7, 8

Question 2

List the flow cytometry markers for B-Cells

Answer 2

CD 10, 19, 20, 22

Question 3

List the flow cytometry markers for Myeloid Cells

Answer 3

CD 33, 34, 117, MPO

Question 4

Name the three Philadelphia chromosome-negative, classical myeloproliferative neoplasms and describe key pathophysiological features shared by these neoplasms

Answer 4

• Polycythemia vera
• Essential thrombocythemia
• Primary myelofibrosis

All three of these myeloproliferative neoplasms arise due to acquired somatic mutation at the level of hematopoietic stem cell or progenitor cell which results in abnormal expansion of MATURE myeloid cells.

Question 5

Name the two key genes most often mutated in the Philadelphia chromosome-negative myeloproliferative neoplasms

Answer 5

• JAK2 [V617F mutation] - leads to activation of JAK/STAT signaling
• CALR mutations - lead to activation of JAK/STAT signaling

Question 6

Describe which mutations cause the different Philadelphia chromosome-negative myeloproliferative neoplasms

Answer 6

• PV: essentially all have the JAK2-V617F mutation
• ET/PMF: 50% have the JAK2-V617F mutation
• ET/PMF: 30% have the CALR mutation
• MPL muations are rare for all three
• ET/PMF: 10% are triple-negative [no JAK2, CALR, or MPL mutation] - associated with poor prognosis

Question 7

List five causes of reactive or secondary thrombocytosis

Answer 7

• trauma
• iron deficiency
• malignancy
• acute infection
• MPL receptor agonists

Question 8

Describe the clinical features, complications, and treatment of essential thrombocytosis [describe the different risk levels too]